3 recruiting. 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 2 |
| Phase 1 | 1 | Recruiting 1 |
Follow Cytochrome P-450 CYP2C8: new trials by email Literature Review of Cytochrome P-450 CYP2C8 trials Research Report on Cytochrome P-450 CYP2C8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions EYP651/Vonafexor low dose, EYP651/Vonafexor high dose, EYP651/CYP3A4 inhibitor - Healthy Adult Male and Female Volunteers | Phase 1 | Recruiting | Enyo Pharma | 40 | 2025-10-28 | 2026-02-27 |
Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Glioma (1) · Leukemia, Myeloid, Acute (1) · Thyroid Neoplasms (1)
Rigel Pharmaceuticals (2) · Enyo Pharma (1)
France (1) · Spain (1) · United States (1)
2025 (1)